"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 3 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 1 | 9 | 10 |
| 2003 | 0 | 4 | 4 |
| 2004 | 3 | 11 | 14 |
| 2005 | 6 | 3 | 9 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 4 | 11 |
| 2008 | 12 | 5 | 17 |
| 2009 | 11 | 6 | 17 |
| 2010 | 14 | 4 | 18 |
| 2011 | 14 | 5 | 19 |
| 2012 | 21 | 15 | 36 |
| 2013 | 24 | 10 | 34 |
| 2014 | 25 | 11 | 36 |
| 2015 | 38 | 17 | 55 |
| 2016 | 31 | 19 | 50 |
| 2017 | 34 | 18 | 52 |
| 2018 | 50 | 21 | 71 |
| 2019 | 29 | 26 | 55 |
| 2020 | 21 | 21 | 42 |
| 2021 | 24 | 21 | 45 |
| 2022 | 3 | 33 | 36 |
| 2023 | 3 | 12 | 15 |
| 2024 | 22 | 23 | 45 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 Jan 09; 68(1):81-94.
-
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Dec 19; 144(25):2678-2681.
-
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol. 2024 Dec 18; 17(1):125.
-
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 2025 Jan 01; 131(1):e35661.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II?trial. Future Oncol. 2024; 20(38):3065-3075.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care? Expert Rev Hematol. 2024 Nov; 17(11):769-780.